EW
Edwards Lifesciences CorpPrice & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted gross profit margin non-GAAP | 78.2% | Q1 2026 | — |
|
|
|||
| Constant currency sales growth non-GAAP | 12.7% | Q1 2026 | — |
| SG&A as a percentage of sales | 31.7% | Q1 2026 | — |
| Surgical constant currency sales growth non-GAAP | 5.9% | Q1 2026 | — |
| Surgical global sales | $276M | Q1 2026 | — |
| Surgical sales growth | 10.1% | Q1 2026 | — |
| TAVR sales growth | 14.4% | Q1 2026 | — |
| TMTT sales | $173M | Q1 2026 | — |
| Adjusted operating profit margin non-GAAP | 23.7% | the fourth quarter | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EW
this stock
Edwards Lifesciences Corp
|
$53.09B | +8.2% | +11.5% | 49.1 | 2.0% |
|
ABT
Abbott Laboratories
|
$163.61B | -24.7% | +5.7% | 26.3 | 1.3% |
|
SYK
Stryker Corp
|
$126.42B | -5.9% | +11.2% | 38.2 | 1.8% |
|
MDT
Medtronic plc
|
$107.36B | -12.0% | +8.4% | 22.5 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.54B | -53.0% | +5.5% | 18.7 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EW | -2.3% | +7.3% | +9.1% | +1.9% | +8.2% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -3.7% | +3.2% | +0.1% | +0.8% | -2.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.